Supplementary Data


Supplementary Table 1. Patient and treatment characteristics of ICI monotherapy cohort.

		Black	White	Hispanic
Ν		58	78	29
Age at diagnosis		62.8	63.2	61.2
Age at ICI initiation		64.3	65.4	62.3
Sex				
	Male	47 (81.0)	61 (78.2)	17 (58.6)
	Female	11 (19.0)	17 (21.8)	12 (41.4)
Smoking status*				
	Yes	48 (82.8)	70 (89.7)	19 (65.5)
	Never smoker	9 (15.5)	8 (10.3)	10 (34.5)
	Smoker at diagnosis	14 (24.1)	31 (39.7)	7 (24.1)
	Unknown	1 (1.7)	0 (0)	0 (0)
Alcohol		,		
	Yes	17 (29.3)	35 (44.9)	10 (34.5)
	No	36 (62.1)	33 (42.3)	19 (65.5)
	Unknown	5 (8.6)	10 (12.8)	0 (0)
Cancer		,		
	Lung	49 (84.5)	60 (76.9)	23 (79.3)
	Adenocarcinoma	34 (69.4)	36 (60.0)	17 (73.9)
	Squamous	13 (26.5)	15 (25.0)	6 (26.0)
	Small cell	2 (4.1)	6 (10.0)	0 (0)
	NSCLC (NOS)	0 (0)	3 (5.0)	0 (0)
	Head and neck SCC	9 (18.4)	18 (23.1)	6 (20.7)
ECOG	000			
	0	7 (12.1)	12 (15.4)	6 (20.7)
	1	22 (37.9)	32 (41.0)	14 (48.3)
	2	17 (29.3)	22 (28.2)	5 (17.2)
	3	3 (5.2)	6 (7.7)	3 (10.3)
	4	1 (1.7)	0 (0)	0 (0)
	Unknown	8 (13.8)	6 (7.7)	1 (3.4)
Number of Metastasis*				
	0	8 (13.8)	11 (14.1)	4 (13.7)
	Contralateral lung	4 (6.9)	2 (2.6)	5 (17.2)
	only 1	17 (29.3)	37 (47.4)	1 (3.4)
	2	21 (36.2)	14 (17.9)	15 (51.7)
	3	4 (6.9)	11 (14.1)	3 (10.3)
	4+	4 (6.9)	3 (3.8)	1 (3.4)
	Any brain	9 (15.5)	18 (23.1)	8 (27.6)
Prior systemic therapy (metastasis (all)			
,	0	9 (15.5)	14 (17.9)	5 (17.2)
	1	28 (48.3)	42 (53.8)	16 (55.2)
	2	15 (25.9)	14 (17.9)	4 (13.8)
	3	4 (6.9)	4 (5.1)	1 (3.4)
	4+	2 (3.4)	4 (5.1)	3 (10.3)

Prior systemic therapy (concurrent and adjuvant chemo excluded)						
	0	12 (20.7)	21 (26.9)	6 (20.7)		
	1	29 (50.0)	43 (55.1)	15 (51.7)		
	2	12 (20.7)	7 (9.0)	4 (13.8)		
	3	3 (5.2)	3 (3.8)	1 (3.4)		
	4+	2 (3.4)	4 (5.1)	3 (10.3)		
ICI treatment						
	Nivolumab	36 (62.1)	46 (59.0)	15 (51.7)		
	Pembrolizumab	22 (37.9)	32 (41.0)	14 (48.3)		
Prior radiation anywhere*						
	Yes	39 (67.2)	63 (80.8)	17 (58.6)		
	No	19 (32.8)	15 (19.2)	12 (41.4)		
PD-L1 status (NSCLC)						
	0%	2 (4.3)	4 (7.4)	4 (17.4)		
	1-49%	7 (14.9)	4 (7.4)	3 (13.0)		
	>50%	12 (25.5)	14 (25.9)	7 (30.4)		
	Unknown	26 (55.3)	32 (59.3)	9 (39.1)		
*p<0.05 for Hispanic vs. White						


Supplementary Figure 1. Patient and disease characteristics with significant differences among the race/ethnic groups for the entire cohort (ICI monotherapy and chemo/ICI combination therapy). A) Smoking status, B) alcohol consumption, and C) number of metastatic sites.

Α.




SupplementaryFigure2.Cohortcharacteristics with significant differencesamong the race/ethnic groups for the ICImonotherapy cohort.A)Smoking status andB) number of metastatic sites.


Α.




Β.




Supplementary Figure 3. Radiation treatment differed significantly as a function of race/ethnicity. A) entire cohort and B) ICI monotherapy cohort.




Supplementary Figure 4. ORR as a function of cohort characteristics with significant differences among the race/ethnic groups for the entire cohort (ICI monotherapy and chemo/ICI combination therapy). A) Smoking status, B) alcohol consumption, C) number of metastatic sites, and D) history of radiation treatment. CR- complete response; PR- partial response; SD- stable disease; PD- progressive disease.




Supplementary Figure 5. ORR as a function of cohort characteristics with significant differences among the race/ethnic groups for the ICI monotherapy cohort. A) Smoking status, B) number of metastatic sites, and C) history of radiation treatment. CR- complete response; PR- partial response; SD- stable disease; PD- progressive disease.








Supplemental Figure 6: Toxicity and treatment typein the entire cohort. A) treatment type by race/ethnicityand B) toxicity by treatment type. P values weredetermined by two-sided Chi-square tests.




Β.



Supplemental Figure 7: Toxicity and treatment type in

the monotherapy cohort. A) treatment type by race/ethnicity and **B)** toxicity by treatment type. P values were determined by two-sided Chi-square tests



Supplementary Table 2. p16 status and response among oropharyngeal cancers by race/ethnicity.

Race/Ethnicity	<u>p16 status</u>	Response type
Black	unknown	Progression
Black	unknown	Progression
White	p16+	Partial response
White	p16+	Progression
White	p16+	Progression
White	p16+	Progression
White	p16-	Progression
White	p16-	Progression
Hispanic	p16+	Progression

Supplementary Table 3. Severe irAEs resulting in steroid administration or ICI cessation with summary of specific severe irAEs.

	<u>Black</u>	<u>White</u>	<u>Hispanic</u>
irAE requiring stop of IO and/or systemic steroids	15 (19.5)	16 (17.2)	6 (15.8)
Stop/hold IO	10	8	4
Steroid only	5	8	2
irAE type			
Ataxia	2	0	0
Meningioencephalitis	1	0	0
Hypophisitis	0	1	0
Adrenal insufficency	1	1	0
Pneumonitis	3	3	3
Tracheobronchitis	0	1	0
Colitis	3	3	2
Hepatitis	2	2	1
Renal Toxicity	0	1	0
Rash	1	2	0
Shingles	1	0	0
ITP	1	0	0
Arthritis	0	2	0